Clinical Trials in Jena, Thuringia
37 recruiting
Showing 1–20 of 36 trials
Recruiting
Phase 1Phase 2
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
MetastasisCastration-Resistant Prostatic Cancer
Merck Sharp & Dohme LLC360 enrolled67 locationsNCT06863272
Recruiting
Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Endometrial Cancer
Merck Sharp & Dohme LLC1,123 enrolled232 locationsNCT06952504
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Carcinoma, Non-Small Cell Lung
Mirati Therapeutics Inc.630 enrolled337 locationsNCT06875310
Recruiting
Phase 3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
AbbVie698 enrolled316 locationsNCT04928846
Recruiting
Phase 3
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Renal Cell Carcinoma
Merck Sharp & Dohme LLC904 enrolled87 locationsNCT07227402
Recruiting
PROCARE - PROstate Cancer Real World Evidence Registry
Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)+2 more
UroTrials Company (GmbH)5,000 enrolled53 locationsNCT06835218
Recruiting
Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Prostate Cancer Metastatic
Merck Sharp & Dohme LLC1,310 enrolled281 locationsNCT06136624
Recruiting
Phase 2Phase 3
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Urothelial Cancer
Bristol-Myers Squibb470 enrolled157 locationsNCT07106762
Recruiting
Phase 2Phase 3
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
AbbVie430 enrolled53 locationsNCT07155187
Recruiting
Phase 4
Asciminib Roll-over Study
Chronic Myelogenous LeukemiaLeukemia, Myelogenous, Chronic, BCR-ABL Positive
Novartis Pharmaceuticals347 enrolled84 locationsNCT04877522
Recruiting
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals800 enrolled111 locationsNCT05344469
Recruiting
A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis
Multiple Sclerosis
Novartis Pharmaceuticals700 enrolled108 locationsNCT06551519
Recruiting
Phase 1
An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis
Rheumatoid Arthritis
Novartis Pharmaceuticals57 enrolled12 locationsNCT07029555
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Advanced Renal Cell Carcinoma (RCC)
Bristol-Myers Squibb234 enrolled71 locationsNCT07293351
Recruiting
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
Breast Neoplasms
Novartis Pharmaceuticals3,250 enrolled267 locationsNCT06830720
Recruiting
Phase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Multiple Sclerosis Spasticity
Celgene200 enrolled53 locationsNCT06782490
Recruiting
Phase 1Phase 2
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Non-Small-Cell Lung Carcinoma
AbbVie252 enrolled55 locationsNCT06772623
Recruiting
German Dementia Registry
Dementia Disorder
RWTH Aachen University5,000 enrolled24 locationsNCT07433010
Recruiting
Phase 2
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
Scleroderma, Diffuse
Novartis Pharmaceuticals96 enrolled80 locationsNCT06655896
Recruiting
Phase 2
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Urinary Bladder NeoplasmsCarcinoma In SituNon-Muscle Invasive Bladder Neoplasms
Merck Sharp & Dohme LLC308 enrolled89 locationsNCT06833073